Literature DB >> 17697883

Development of monoclonal antibodies to integrin receptors.

E A Wayner1, B G Hoffstrom.   

Abstract

Integrins are heterodimeric cell surface receptors composed of an alpha and a beta subunit. They are involved in homotopic and heterotopic cell adhesion and also function as receptors for extracellular matrix molecules such as collagen, fibronectin and laminin. The family to which an integrin belongs is defined by the presence of a particular beta subunit paired with a unique alpha subunit. In this chapter we describe methods to produce monoclonal antibodies to the family of integrin subunits characterized by beta1 and provide detailed instructions for the development of a monoclonal antibody to the alpha6 integrin receptor expressed by human prostate carcinoma cells (PC3 cells). Data are presented that correlate the functional capabilities of an antibody with its biochemical characterization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697883     DOI: 10.1016/S0076-6879(07)26007-0

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  10 in total

1.  Integrin α-3 ß-1's central role in breast cancer, melanoma and glioblastoma cell aggregation revealed by antibodies with blocking activity.

Authors:  Daniel F Lusche; Michael R Klemme; Benjamin A Soll; Ryan J Reis; Cristopher C Forrest; Tiffany S Nop; Deborah J Wessels; Brian Berger; Rebecca Glover; David R Soll
Journal:  MAbs       Date:  2019-04-16       Impact factor: 5.857

2.  Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Peter A Chiarelli; Robert S Miyaoka; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

3.  Monoclonal antibodies against Muscleblind-like 3, a protein with punctate nuclear localization.

Authors:  Kyung-Soon Lee; K A Lewis; Susan Tom; Elizabeth A Wayner; Edith H Wang
Journal:  Hybridoma (Larchmt)       Date:  2011-04

4.  Glypican-3-Targeted 227Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma.

Authors:  Kevin P Labadie; Donald K Hamlin; Aimee Kenoyer; Sara K Daniel; Alan F Utria; Andrew D Ludwig; Heidi L Kenerson; Lily Li; Jonathan G Sham; Delphine L Chen; Johnnie J Orozco; Raymond S Yeung; Chris Orvig; Yawen Li; D Scott Wilbur; James O Park
Journal:  J Nucl Med       Date:  2021-11-12       Impact factor: 11.082

5.  Developing and mature human granulocytes express ELP 6 in the cytoplasm.

Authors:  Lori A Wagner; Shuping Wang; Elizabeth A Wayner; Clarissa Christensen; Sherrie J Perkins; Gavin W Ward; Robert B Weiss; Diane M Dunn; Michael J Redd; Gerald J Spangrude; Gerald J Gleich
Journal:  Hum Antibodies       Date:  2013

Review 6.  Antibodies targeting extracellular domain of connexins for studies of hemichannels.

Authors:  Manuel A Riquelme; Rekha Kar; Sumin Gu; Jean X Jiang
Journal:  Neuropharmacology       Date:  2013-03-13       Impact factor: 5.250

7.  The range of human APOBEC3H sensitivity to lentiviral Vif proteins.

Authors:  Melody M H Li; Lily I Wu; Michael Emerman
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

8.  A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs.

Authors:  V Kraig Abrams; Billanna Hwang; Marina Lesnikova; M John Gass; Elizabeth Wayner; Cristina Castilla-Llorente; George E Georges; Richard A Nash
Journal:  Vet Immunol Immunopathol       Date:  2009-12-29       Impact factor: 2.046

9.  Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.

Authors:  Jonathan G Sham; Forrest M Kievit; John R Grierson; Robert S Miyaoka; Matthew M Yeh; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park
Journal:  J Nucl Med       Date:  2014-03-13       Impact factor: 10.057

10.  Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.

Authors:  Eun Ji Gang; Hye Na Kim; Yao-Te Hsieh; Yongsheng Ruan; Heather A Ogana; Solomon Lee; Jennifer Pham; Huimin Geng; Eugene Park; Lars Klemm; Cheryl L Willman; William L Carroll; Steven D Mittelman; Etan Orgel; Matthew J Oberley; Chintan Parekh; Hisham Abdel-Azim; Deepa Bhojwani; Alan S Wayne; Adèle De Arcangelis; Elisabeth Georges-Labouesse; Elizabeth Wayner; Halvard Bonig; Aspram Minasyan; Johanna Ten Hoeve; Thomas G Graeber; Markus Müschen; Nora Heisterkamp; Yong-Mi Kim
Journal:  Blood       Date:  2020-07-09       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.